Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A drug given to organ donors may help kidneys work faster after transplant

NCT ID NCT02907554

Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This trial tests whether giving a single dose of cyclosporine A to deceased organ donors before their kidneys are removed can reduce the chance of delayed graft function in recipients. Delayed graft function means the kidney does not start working right away, often requiring dialysis. The study compares kidneys from donors who received cyclosporine A against those who received a placebo, tracking how well the kidneys function during the first year after transplant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cyclosporine A given to the deceased organ donor before kidney removal
What this could lead to
If it works, this simple pretreatment could reduce the need for dialysis after kidney transplant and improve early graft function.
What could go wrong
This is a single-drug approach in a complex transplant setting; benefits may be modest or not outweigh risks like infection or kidney toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

648 people

The number who actually took part.

Started

Dec 2017

Finished

Apr 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For organ donors: * Male and females aged 18 to 80 years * Brain death Inclusion criteria for organ recipients: * Male and females aged 18 to 80 years * Indication of kidney transplantation * Informed consent Exclusion Criteria: For organ donors: * Contra-indication for multiorgan procurement (infections, cancer, etc) * Preexistent chronic renal failure. * Refusal for organ procurement by the donor (confirmed by the French national register or reported by the next-of-kin). Exclusion criteria for organ recipients: * Need for a double kidney transplantation. * Need for a multiorgan transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain death are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Brain Death chronic kidney disease Delayed Graft Function

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain death Kidney transplantation

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.